Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

190.79USD
4:38pm BST
Change (% chg)

$3.19 (+1.70%)
Prev Close
$187.60
Open
$188.30
Day's High
$190.88
Day's Low
$186.88
Volume
157,223
Avg. Vol
495,203
52-wk High
$217.00
52-wk Low
$142.83

Select another date:

Fri, Sep 14 2018

Photo

Allergan says revenue from aesthetics unit may double by 2025

NEW YORK Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

CORRECTED-UPDATE 1-Allergan says revenue from aesthetics unit may double by 2025

NEW YORK, Sept 14 Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

UPDATE 1-FDA rejects Allergan's Esmya fibroid treatment

Aug 21 Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

FDA declines to approve Allergan's Esmya

Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

FDA declines to approve Allergan's Esmya

Aug 21 Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

Spain's Almirall bets on dermatology with $650 million U.S. deal

Spanish pharmaceutical company Almirall said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.

UPDATE 1-Spain's Almirall bets on dermatology with $650 mln U.S. deal

Aug 3 Spanish pharmaceutical company Almirall said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.

Spain's Almirall to buy U.S. dermatology portfolio from Allergan

Aug 3 Spanish pharmaceutical company Almirall SA said on Friday it has agreed to buy a portfolio of five brands from U.S. firm Allergan for up to $650 million in cash.

Allergan sues Pfizer over costs of opioid litigation

Allergan Plc on Thursday sued Pfizer Inc to require its rival to cover any damages it is forced to pay as a result of hundreds of lawsuits claiming Allergan deceptively marketed an opioid it acquired from a company Pfizer bought.

Allergan sues Pfizer over costs of opioid litigation

Allergan Plc on Thursday sued Pfizer Inc to require its rival to cover any damages it is forced to pay as a result of hundreds of lawsuits claiming Allergan deceptively marketed an opioid it acquired from a company Pfizer bought.

Select another date: